KOSUNI KOREA
Korean News in English
Business

Keytruda Biosimilar Development by Samsung Bioepis: Efficacy and Side Effect Comparison

Published September 27, 2026 · 2 views
Keytruda Biosimilar Development by Samsung Bioepis: Efficacy and Side Effect Comparison

Current Status of Samsung Bioepis' Keytruda Biosimilar Development

South Korea's Samsung Bioepis is actively developing a biosimilar to Keytruda (Pembrolizumab), with its first regulatory application underway in the domestic market. The company aims to maintain a leading position in the global biosimilar market by 2026, strategically positioning itself ahead of the U.S. and European patent expirations set for 2025-2026. Additionally, Samsung Bioepis is channeling revenue from its biosimilar business into developing ADC (Antibody-Drug Conjugate) new drugs.

키트루다 암 치료제 삼성바이오에피스 효과: 부작용과 비교 설명 이미지

Completion of Phase 3 Clinical Trials and Patent Expiration Timeline

Samsung Bioepis has confirmed equivalence in its Keytruda biosimilar through successful phase 3 clinical trials. With U.S. and European patents set to expire soon, competition among Korean biosimilar developers is intensifying. Samsung Bioepis and Celltrion are leading the development of Keytruda biosimilars, with the '43 trillion won Keytruda patent expiration' approaching rapidly as of August 21, 2025, signaling heightened market competition.

Expansion of Indications and Current Clinical Research

The approved indications for Keytruda have been expanded to include first-line treatment for bile duct cancer and early-stage cervical cancer. Samsung Bioepis has initiated SB27, a global phase 3 clinical trial related to these expanded indications. On April 5, 2024, Samsung Bioepis launched the SB27 global phase 3 trial, followed by regulatory approval for Keytruda's indication expansion on April 16, 2024. Additionally, on August 26, 2024, a phase 3 clinical trial comparing intravenous and subcutaneous formulations of Keytruda for lung cancer was approved.

Differentiation Strategy Against Competitors

While competing with Celltrion in the biosimilar market, Samsung Bioepis is focusing on developing its Keytruda biosimilar. Following regulatory approval for its 'Keytruda biosimilar' phase 1 trial on November 25, 2023, Samsung Bioepis has actively pursued expanded indications and combination therapy research through November 6, 2024, aiming to differentiate itself from Celltrion in the Keytruda biosimilar development race.

ADC Drug Development and Open Innovation Strategy

As part of its strategy, Samsung Bioepis is investing revenue from biosimilar sales into ADC (Antibody-Drug Conjugate) new drug development. The company has also transitioned post-spinoff to become an independent R&D-focused entity, strengthening its research capabilities since July 18, 2025. Additionally, Samsung Bioepis has signed agreements with two companies under its open innovation program and is sharing patient prescription data for Humira biosimilars as part of ongoing initiatives.

Competition in the Nectin-4 ADC 'Padsev' Market

Samsung Bioepis is entering the competitive market for Nectin-4 ADC 'Padsev' as a latecomer. On February 6, 2026, Pfizer announced an all-in commitment to its Nectin-4 ADC Padsev, intensifying Samsung Bioepis's position in this emerging field and highlighting its efforts to build competitiveness in new drug development.

Market Outlook and Future Plans

Samsung Bioepis aims to maintain a leading position in the global biosimilar market by 2026, capitalizing on the U.S. and European patent expiration of Keytruda in 2025-2026. The company plans to leverage revenue from its biosimilar business to invest in ADC drug development for long-term growth. Through ongoing expansion of indications and clinical research until 2026, Samsung Bioepis aims to increase market share.

Key Information to Verify

As of August 10, 2026, Samsung Bioepis is in the process of its first domestic regulatory application for the Keytruda biosimilar. The company plans to secure a leading position ahead of the U.S. and European patent expiration dates (2025-2026). Additionally, Samsung Bioepis is investing biosimilar revenue into ADC drug development, having launched the SB27 global phase 3 trial on April 5, 2024. On February 6, 2026, Pfizer's all-in commitment to Nectin-4 ADC Padsev has intensified competition for Samsung Bioepis as a late entrant.

Frequently Asked Questions

Which competitors is Samsung Bioepis facing in Keytruda biosimilar development?

Samsung Bioepis collaborates with Celltrion to lead the development of Keytruda biosimilars. With the '43 trillion won Keytruda patent expiration' approaching rapidly as of August 21, 2025, competition between Samsung Bioepis and Celltrion for market leadership has intensified.

How is Samsung Bioepis investing in ADC drug development?

Samsung Bioepis is channeling revenue from its biosimilar business into ADC (Antibody-Drug Conjugate) new drug development. This strategy, solidified since the company's spinoff on July 18, 2025, aims to secure long-term growth.

How have Keytruda's indications been expanded?

Keytruda's approved indications were expanded to include first-line treatment for bile duct cancer and early-stage cervical cancer. Samsung Bioepis is conducting research related to these expansions through the SB27 global phase 3 trial. Additionally, a phase 3 clinical trial comparing intravenous and subcutaneous formulations of Keytruda for lung cancer was approved on August 26, 2024.

Frequently Asked Questions

Samsung Bioepis is targeting market share growth in the global biosimilar sector through its Keytruda biosimilar development. The company aims to secure a leading position by capitalizing on the U.S. and European patent expiration of Keytruda in 2025-2026, while also investing biosimilar revenue into ADC drug development. Since launching the SB27 global phase 3 trial on April 5, 2024, Samsung Bioepis has been actively expanding indications and researching combination therapies. With Pfizer's all-in commitment to Nectin-4 ADC Padsev announced on February 6, 2026, Samsung Bioepis faces intensified competition as a late entrant in this emerging market.

Related Articles

You can view similar articles on this topic all at once.

View Related Articles

FAQ

Which competitors is Samsung Bioepis facing in Keytruda biosimilar development?

Samsung Bioepis collaborates with Celltrion to lead the development of Keytruda biosimilars. With the '43 trillion won Keytruda patent expiration' approaching rapidly as of August 21, 2025, competition between Samsung Bioepis and Celltrion for market leadership has intensified.

How is Samsung Bioepis investing in ADC drug development?

Samsung Bioepis is channeling revenue from its biosimilar business into ADC (Antibody-Drug Conjugate) new drug development. This strategy, solidified since the company's spinoff on July 18, 2025, aims to secure long-term growth.

How have Keytruda's indications been expanded?

Keytruda's approved indications were expanded to include first-line treatment for bile duct cancer and early-stage cervical cancer. Samsung Bioepis is conducting research related to these expansions through the SB27 global phase 3 trial. Additionally, a phase 3 clinical trial comparing intravenous and subcutaneous formulations of Keytruda for lung cancer was approved on August 26, 2024.

Korean Source

This article is an English localization of a Korean-language report from BlogScore. Original: 키트루다 암 치료제 삼성바이오에피스 효과: 부작용과 비교